{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T12:33:26Z","timestamp":1759667606112,"version":"3.37.3"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"DOI":"10.13039\/501100005795","name":"Chang Gung Memorial Hospital, Linkou","doi-asserted-by":"publisher","award":["CMRPG-381091"],"award-info":[{"award-number":["CMRPG-381091"]}],"id":[{"id":"10.13039\/501100005795","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Proteom"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s12014-017-9164-y","type":"journal-article","created":{"date-parts":[[2017,8,2]],"date-time":"2017-08-02T11:05:39Z","timestamp":1501671939000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Down-regulation of metabolic proteins in hepatocellular carcinoma with portal vein thrombosis"],"prefix":"10.1186","volume":"14","author":[{"given":"Wei-Chen","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong-Shiue","family":"Chou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ting-Jung","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chen-Fang","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pao-Yueh","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hsiu-Ying","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsung-Han","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kun-Ming","family":"Chan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,8,2]]},"reference":[{"key":"9164_CR1","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/S0140-6736(11)61347-0","volume":"379","author":"A Forner","year":"2012","unstructured":"Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet. 2012;379:1245\u201355.","journal-title":"Lancet"},{"key":"9164_CR2","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1097\/01.sla.0000254368.65878.da","volume":"245","author":"M Minagawa","year":"2007","unstructured":"Minagawa M, Ikai I, Matsuyama Y, Yamaoka Y, Makuuchi M. Staging of hepatocellular carcinoma: assessment of the Japanese TNM and AJCC\/UICC TNM systems in a cohort of 13,772 patients in Japan. Ann Surg. 2007;245:909\u201322.","journal-title":"Ann Surg"},{"key":"9164_CR3","doi-asserted-by":"crossref","first-page":"2568","DOI":"10.1016\/j.ejca.2011.07.002","volume":"47","author":"YH Chun","year":"2011","unstructured":"Chun YH, Kim SU, Park JY, Kim DY, Han KH, Chon CY, et al. Prognostic value of the 7th edition of the AJCC staging system as a clinical staging system in patients with hepatocellular carcinoma. Eur J Cancer. 2011;47:2568\u201375.","journal-title":"Eur J Cancer"},{"key":"9164_CR4","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1046\/j.0007-1323.2001.02034.x","volume":"89","author":"W-C Lee","year":"2002","unstructured":"Lee W-C, Jeng L-B, Chen M-F. Estimation for prognosis after hepatectomy for hepatocellular carcinoma. Br J Surg. 2002;89:311\u20136.","journal-title":"Br J Surg"},{"key":"9164_CR5","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/S0168-8278(02)00360-4","volume":"38","author":"H Imamura","year":"2003","unstructured":"Imamura H, Matsuyama Y, Tanaka E, Ohkubo T, Hasegawa K, Miyagawa S, et al. Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol. 2003;38:200\u20137.","journal-title":"J Hepatol"},{"key":"9164_CR6","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1056\/NEJM199603143341104","volume":"334","author":"V Mazzferro","year":"1996","unstructured":"Mazzferro V, Regalia E, Doci R, Andreola S, Morabito A, Bozzetti F, et al. Liver transplantation for the treatment of small hepatocellular carcinoma in patients with cirrhosis. N Engl J Med. 1996;334:693\u20139.","journal-title":"N Engl J Med"},{"key":"9164_CR7","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1001\/archsurg.2007.39","volume":"143","author":"MA Zimmerman","year":"2008","unstructured":"Zimmerman MA, Ghobrial M, Tong MJ, Hiatte R, Cameron AM, Hong J, et al. Recurrence of hepatocellular carcinoma following liver transplantation. A review of of preoperative and postoperative prognostic indicators. Arch Surg. 2008;143:182\u20138.","journal-title":"Arch Surg"},{"key":"9164_CR8","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1097\/00000658-198510000-00001","volume":"202","author":"S Iwatsuki","year":"1985","unstructured":"Iwatsuki S, Gordon R, Shaw B, Starzl T. Role of liver transplantation in cancer therapy. Ann Surg. 1985;202:401\u20139.","journal-title":"Ann Surg"},{"key":"9164_CR9","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1097\/SLA.0b013e31823e70a3","volume":"255","author":"BJ Shrager","year":"2012","unstructured":"Shrager BJ, Jibara G, Schwartz M, Roayaie S. Resection of hepatocellular carcinoma without cirrhosis. Ann Surg. 2012;255:1135\u201343.","journal-title":"Ann Surg"},{"key":"9164_CR10","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1016\/j.ejso.2015.05.024","volume":"41","author":"WC Lee","year":"2015","unstructured":"Lee WC, Lee CF, Cheng CH, Wu TJ, Chou HS, Wu TH, et al. Outcomes of liver resection for hepatocellular carcinoma in liver transplantation era. Eur J Surg Oncol. 2015;41:1144\u201352.","journal-title":"Eur J Surg Oncol"},{"key":"9164_CR11","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1097\/00000658-200203000-00009","volume":"235","author":"R Poon","year":"2002","unstructured":"Poon R, Fan S, Lo C, Liu C, Wong J. Long-term survival and pattern of recurrence after resection of small hepatocellular carcinoma in patients with preserved liver function: implications for a strategy of salvage liver transplantation. Ann Surg. 2002;235:373\u201382.","journal-title":"Ann Surg"},{"key":"9164_CR12","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1245\/s10434-012-2513-1","volume":"20","author":"M Rodriguez-Peralvarez","year":"2013","unstructured":"Rodriguez-Peralvarez M, Luong TV, Andreana L, Meyer T, Dhillon AP, Burroughs AK. A systematic review of microvascular invasion in hepatocellular carcinoma: diagnostic and prognostic variability. Ann Surg Oncol. 2013;20:325\u201339.","journal-title":"Ann Surg Oncol"},{"key":"9164_CR13","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1002\/lt.20472","volume":"11","author":"TM Pawlik","year":"2005","unstructured":"Pawlik TM, Delman KA, Vauthey JN, Nagorney DM, Ng IO, Ikai I, et al. Tumor size predicts vascular invasion and histologic grade: implications for selection of surgical treatment for hepatocellular carcinoma. Liver Transpl. 2005;11:1086\u201392.","journal-title":"Liver Transpl"},{"key":"9164_CR14","first-page":"277","volume":"211","author":"Liver Cancer Study Group of Japan","year":"1990","unstructured":"Liver Cancer Study Group of Japan. Primary liver cancer in Japan: clinicopathologic features and results of surgical treatment. Ann Surg. 1990;211:277\u201387.","journal-title":"Ann Surg"},{"key":"9164_CR15","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1002\/hep.23485","volume":"51","author":"G Cabibbo","year":"2010","unstructured":"Cabibbo G, Enea M, Attanasio M, Bruix J, Craxi A, Camma C. A meta-analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma. Hepatology. 2010;51:1274\u201383.","journal-title":"Hepatology"},{"key":"9164_CR16","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1111\/j.1478-3231.2008.01957.x","volume":"29","author":"P Tandon","year":"2009","unstructured":"Tandon P, Garcia-Tsao G. Prognostic indicators in hepatocellular carcinoma: a systematic review of 72 studies. Liver Int. 2009;29:502\u201310.","journal-title":"Liver Int"},{"key":"9164_CR17","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1111\/j.1440-1746.2007.05112.x","volume":"23","author":"KW Park","year":"2008","unstructured":"Park KW, Park J-W, Choi JI, Kim TH, Kim SH, Park HS, et al. Survival analysis of 904 patients with hepatocellular carcinoma in a hepatitis B virus-endemic area. J Gastroenterol Hepatol. 2008;23:467\u201373.","journal-title":"J Gastroenterol Hepatol"},{"key":"9164_CR18","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1002\/pmic.200401141","volume":"5","author":"C Li","year":"2005","unstructured":"Li C, Tan Y, Zhou H, Ding S, Li S, Ma D, et al. Proteomic analysis of hepatitis B virus-associated Hepatocellular carcinoma: identification of potential tumor markers. Proteomics. 2005;5:1125\u201339.","journal-title":"Proteomics"},{"key":"9164_CR19","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1002\/pmic.200800196","volume":"8","author":"SY Hsieh","year":"2008","unstructured":"Hsieh SY, Zhuang FH, Wu YT, Chen JK, Lee YL. Profiling the proteome dynamics during the cell cycle of human hepatoma cells. Proteomics. 2008;8:2872\u201384.","journal-title":"Proteomics"},{"key":"9164_CR20","doi-asserted-by":"crossref","first-page":"115","DOI":"10.3350\/cmh.2015.21.2.115","volume":"21","author":"HY Woo","year":"2015","unstructured":"Woo HY, Heo J. New perspectives on the management of hepatocellular carcinoma with portal vein thrombosis. Clin Mol Hepatol. 2015;21:115\u201321.","journal-title":"Clin Mol Hepatol"},{"key":"9164_CR21","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1002\/cncr.23684","volume":"113","author":"K-H Han","year":"2008","unstructured":"Han K-H, Seong J, Kim JK, Ahn SH, Lee DY, Chon CY. Pilot clinical trial of localized concurrent chemoradiation therapy for locally advanced hepatocellular carcinoma with portal vein thrombosis. Cancer. 2008;113:995\u20131003.","journal-title":"Cancer"},{"key":"9164_CR22","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s00280-006-0239-0","volume":"59","author":"JW Jang","year":"2006","unstructured":"Jang JW, Bae SH, Choi JY, Oh HJ, Kim MS, Lee SY, et al. A combination therapy with transarterial chemo-lipiodolization and systemic chemo-infusion for large extensive hepatocellular carcinoma invading portal vein in comparison with conservative management. Cancer Chemother Pharmacol. 2006;59:9\u201315.","journal-title":"Cancer Chemother Pharmacol"},{"key":"9164_CR23","doi-asserted-by":"crossref","first-page":"e0154986","DOI":"10.1371\/journal.pone.0154986","volume":"11","author":"YY Cho","year":"2016","unstructured":"Cho YY, Lee M, Kim HC, Chung JW, Kim YH, Gwak GY, et al. Radioembolization is a safe and effective treatment for hepatocellular carcinoma with portal vein thrombosis: a propensity score analysis. PLoS ONE. 2016;11:e0154986.","journal-title":"PLoS ONE"},{"key":"9164_CR24","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1159\/000367737","volume":"4","author":"CC Lin","year":"2015","unstructured":"Lin CC, Hung CF, Chen WT, Lin SM. Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein thrombosis: impact of early response to 4\u00a0weeks of treatment. Liver Cancer. 2015;4:228\u201340.","journal-title":"Liver Cancer"},{"key":"9164_CR25","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1056\/NEJMe0810213","volume":"360","author":"CB Thompson","year":"2009","unstructured":"Thompson CB. Metabolic enzymes as oncogenes or tumor suppressors. N Engl J Med. 2009;360:813\u20135.","journal-title":"N Engl J Med"},{"key":"9164_CR26","doi-asserted-by":"crossref","first-page":"e1000328","DOI":"10.1371\/journal.pbio.1000328","volume":"8","author":"O Yogev","year":"2010","unstructured":"Yogev O, Yogev O, Singer E, Shaulian E, Goldberg M, Fox TD, et al. Fumarase: a mitochondrial metabolic enzyme and a cytosolic\/nuclear component of the DNA damage response. PLoS Biol. 2010;8:e1000328.","journal-title":"PLoS Biol"},{"key":"9164_CR27","doi-asserted-by":"crossref","first-page":"4675","DOI":"10.1038\/sj.onc.1209594","volume":"25","author":"A King","year":"2006","unstructured":"King A, Selak M, Gottlieb E. Succinate dehydrogenase and fumarate hydratase: linking mitochondrial dysfunction and cancer. Oncogene. 2006;25:4675\u201382.","journal-title":"Oncogene"},{"key":"9164_CR28","doi-asserted-by":"crossref","first-page":"4667","DOI":"10.1158\/1078-0432.CCR-06-2510","volume":"13","author":"G Bratslavsky","year":"2007","unstructured":"Bratslavsky G, Sudarshan S, Neckers L, Linehan L. Pseudohypoxic pathways in renal cell carcinoma. Clin Cancer Res. 2007;13:4667\u201371.","journal-title":"Clin Cancer Res"},{"key":"9164_CR29","doi-asserted-by":"crossref","first-page":"9153","DOI":"10.1158\/0008-5472.CAN-10-1949","volume":"70","author":"H Ashrafian","year":"2010","unstructured":"Ashrafian H, O\u2019Flaherty L, Adam J, Steeples V, Chung Y-L, East P, et al. Expression profiling in progressive stages of fumarate-hydratase deficiency: the contribution of metabolic changes to tumorigenesis. Can Res. 2010;70:9153\u201365.","journal-title":"Can Res"},{"key":"9164_CR30","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.molmed.2016.12.001","volume":"23","author":"GM Fuhler","year":"2017","unstructured":"Fuhler GM, Eppinga H, Peppelenbosch MP. Fumarates and cancer. Trends Mol Med. 2017;23:3\u20135.","journal-title":"Trends Mol Med"},{"key":"9164_CR31","doi-asserted-by":"crossref","first-page":"2680","DOI":"10.1096\/fj.09-146928","volume":"24","author":"B Costa","year":"2010","unstructured":"Costa B, Dettori D, Lorenzato A, Bardella C, Coltella N, Martino C, et al. Fumarase tumor suppressor gene and MET oncogene cooperate in upholding transformation and tumorigenesis. FASEB J. 2010;24:2680\u20138.","journal-title":"FASEB J"},{"key":"9164_CR32","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1038\/sj.bjc.6600936","volume":"89","author":"CPS Potter","year":"2003","unstructured":"Potter CPS, Harris AL. Diagnostic, prognostic and therapeutic implications of carbonic anhydrases in cancer. Br J Cancer. 2003;89:2\u20137.","journal-title":"Br J Cancer"},{"key":"9164_CR33","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S0304-3835(02)00078-2","volume":"188","author":"W-L Chiang","year":"2002","unstructured":"Chiang W-L, Chu S-C, Yang S-S, Li M-C, Lai J-C, Yang S-F, et al. The aberrant expression of cytosolic carbonic anhydrase and its clinical significance in human non-small cell lung cancer. Cancer Lett. 2002;188:199\u2013205.","journal-title":"Cancer Lett"},{"key":"9164_CR34","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1016\/S0024-3205(03)00597-6","volume":"73","author":"W Kuo","year":"2003","unstructured":"Kuo W, Chiang W, Yang S, Yeh K, Yeh C, Hsieh Y, et al. The differential expression of cytosolic carbonic anhydrase in human hepatocellular carcinoma. Life Sci. 2003;73:2211\u201323.","journal-title":"Life Sci"},{"key":"9164_CR35","doi-asserted-by":"crossref","first-page":"36258","DOI":"10.1074\/jbc.M111.265348","volume":"286","author":"YW Teng","year":"2011","unstructured":"Teng YW, Mehedint MG, Garrow TA, Zeisel SH. Deletion of betaine\u2013homocysteine S-methyltransferase in mice perturbs choline and 1-carbon metabolism, resulting in fatty liver and hepatocellular carcinomas. J Biol Chem. 2011;286:36258\u201367.","journal-title":"J Biol Chem"},{"key":"9164_CR36","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1111\/j.1440-1681.2010.05438.x","volume":"37","author":"T-T Yan","year":"2010","unstructured":"Yan T-T, Li Q, Zhang X-H, Wu W-K, Sun J, Li L, et al. Homocysteine impaired endothelial function through compromised vascular endothelial growth factor\/Akt\/endothelial nitric oxide synthase signalling. Clin Exp Pharmacol Physiol. 2010;37:1071\u20137.","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"9164_CR37","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.ymgme.2006.08.011","volume":"90","author":"W-D Lin","year":"2007","unstructured":"Lin W-D, Wang C-H, Lee C-C, Lai C-C, Tsai Y, Tsai F-J. Genetic mutation profile of isovaleric acidemia patients in Taiwan. Mol Genet Metab. 2007;90:134\u20139.","journal-title":"Mol Genet Metab"},{"key":"9164_CR38","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1007\/s10545-010-9080-z","volume":"33","author":"BT Maldegem van","year":"2010","unstructured":"van Maldegem BT, Wanders RJA, Wijburg FA. Clinical aspects of short-chain acyl-CoA dehydrogenase deficiency. J Inherit Metab Dis. 2010;33:507\u201311.","journal-title":"J Inherit Metab Dis"},{"key":"9164_CR39","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1080\/07357900601062321","volume":"24","author":"T Dorai","year":"2006","unstructured":"Dorai T, Sawczuk I, Pastorek J, Wiernik PH, Dutcher JP. Role of carbonic anhydrases in the progression of renal cell carcinoma subtypes: proposal of a unified hypothesis. Cancer Invest. 2006;24:754\u201379.","journal-title":"Cancer Invest"},{"key":"9164_CR40","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJMoa065044","volume":"356","author":"R Motzer","year":"2007","unstructured":"Motzer R, Hutson T, Tomczak P, Michaelson D, Bukowski R, Rixe O, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356:115\u201324.","journal-title":"N Engl J Med"},{"key":"9164_CR41","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa060655","volume":"356","author":"B Escudier","year":"2007","unstructured":"Escudier B, Eisen T, Stadler W, Szczylik C, Qudard S, Siebels M, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Eng J Med. 2007;356:125\u201334.","journal-title":"N Eng J Med"},{"key":"9164_CR42","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","volume":"359","author":"J Llovet","year":"2008","unstructured":"Llovet J, Ricci S, Mazzaferro V, Hilagrd P, Gane E, Blanc J, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378\u201390.","journal-title":"N Engl J Med"},{"key":"9164_CR43","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","volume":"10","author":"A-L Cheng","year":"2009","unstructured":"Cheng A-L, Kang Y-K, Chen Z, Tsao C-J, Qin S, Kim J-S, et al. Efficiency and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind placebo-controlled trial. Lancet Oncol. 2009;10:25\u201334.","journal-title":"Lancet Oncol"}],"container-title":["Clinical Proteomics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12014-017-9164-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,8,2]],"date-time":"2017-08-02T11:05:46Z","timestamp":1501671946000},"score":1,"resource":{"primary":{"URL":"http:\/\/clinicalproteomicsjournal.biomedcentral.com\/articles\/10.1186\/s12014-017-9164-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,2]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["9164"],"URL":"https:\/\/doi.org\/10.1186\/s12014-017-9164-y","relation":{},"ISSN":["1542-6416","1559-0275"],"issn-type":[{"type":"print","value":"1542-6416"},{"type":"electronic","value":"1559-0275"}],"subject":[],"published":{"date-parts":[[2017,8,2]]},"article-number":"29"}}